Abstract
Accumulation of β-amyloid (Aβ) in the brain occurs in the early phase of Alzheimer’s disease (AD), without symptoms of cognitive decline. Therefore, early detection of the accumulation phase is essential to prevent or delay AD. In this study, we investigated the effects of age, sex, apoprotein-E (ApoE) genotype and cognitive dysfunction on the ratio of Aβ1-42, Aβ1-40, and amyloid β precursor protein (APP)669-711 (composite biomarker: CM) in plasma using a sensitive Time of flight mass spectrometry (TOF-MS). In healthy subjects, the average CM value of males aged 30– 59 years was significantly higher than that of females, but no difference was observed between those aged 60 and 79 years. CM values increased considerably after 50 years of age, especially in females. The effect of the ApoE4 genotype on CM was greater in females than in males. The CM value of patients with AD was higher than that of healthy subjects and that of patients with Parkinson’s disease (PD). The CM value of patients with PD complicated by AD was higher than that of patients with PD. These results suggest that the CM value is influenced by age, sex, ApoE4 genotype, and central nervous system disorder. In addition, the CM value could be a reliable biomarker to distinguish not only patients with AD and healthy subjects but also AD and patients with PD. Since the measurement of CM is less invasive to the subjects, the method is helpful for the early detection of accumulation of Aβ before the appearance of AD symptoms. Moreover, this practical method can be used for differential diagnosis among a variety of patients with dementia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the guidelines of the Declaration of Helsinki. The ethics committee approved all procedures involving human subjects at Hokkaido Information University (for healthy people, approved on November 26, 2019 approval number: 2019-31 for patients, approved on July 31, 2020 approval number: 2020-19). Therefore, this study complied with the ethical guidelines for human medical research as per the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labour, and Welfare.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Availability Statement: The data obtained from the “Sukoyaka Health Survey” is not cur-rently in a publicly accessible repository, but is scheduled to be released in 2024 from a publicly accessible repository managed by the DDBJ (DNA Data Bank of Japan) JGA (Japanese Geno-type-phenotype Archive https://www.ddbj.nig.ac.jp/jga/index-e.html).
